



Diagnósticos da América S.A.

Investor Relations
Av. Juruá, 434 - Alphaville, Barueri - SP
55 11 4197-5410
55 11 4197-5509
ir@danet.com.br
www.diagnosticosdaamerica.com.br



MATERIAL FACT Diagnósticos da América S.A. Publicly-Held Company with Authorized Stock Corporate Tax Payer (CNPJ) no. 61.486.650/0001-83

Pursuant to CVM Instruction nr. 358/2002 and the applicable laws in effect, Diagnósticos da América S.A. (Bovespa: DASA3) hereby informs its stockholders and the market of the following:

On October 26th, 2006, Diagnósticos da América S.A. ("DASA") acquired 650,000 quotas or 100% of the capital stock of "Laboratório Atalaia Ltda" ("Atalaia"), a company that provides clinical analysis and imaging services in the city of Goiânia, state capital of Goiás.

The said quotas were valued at R\$ 26,930,000.00, where R\$ 1,930,000.00 refers to the net debt assumed. From the equity value of R\$ 25,000,000.00 to be paid to the sellers, R\$ 22,100,000.00 will be settled today and R\$ 400,000.00 within the next 60 days. The remaining amount of R\$ 2,500,000.00 will be withheld in escrow deposit accounts for as long as six years. An additional amount of R\$ 3,920,000.00, that refers to two Real Estate properties owned by the sellers and Atalaia, will be also acquired by DASA.

Atalaia was founded in 1968 to offer clinical analysis services in the city of Goiânia (Goiás State) and is the local market leader in this segment. The lab holds the PALC certification (Clinical Laboratory Certification Program) and serves around 30,000 patients daily, through 12 patient service centers. Atalaia posted R\$ 19.2 million gross revenues in the last twelve month period from October 2005 to September 2006.

With the Atalaia lab acquisition, DASA assumes the clinical analysis market leadership in Goiânia, one of the fastest growing regions in Brazil over the last years, where around 36% of its population is covered by health insurance plans (ANS, Ipaggo). DASA's strategic plan for the next five years for the acquired lab includes the introduction of new patient service centers, a broader clinical analysis tests portfolio and new imaging services.

This deal was approved on a meeting held on October 26th, 2006 by DASA's Board of Directors. Because the purchase price does not represent a significant investment for DASA as per Act no. 6.404/76, Article 256, Subsection I, Paragraph 1, and this transaction does not have to be submitted to a Special Shareholders' Meeting for ratification. The acquisition of Laboratório Atalaia will also be submitted to the Brazilian Antitrust Commission (CADE) for approval.

São Paulo, October 26th 2006

Marcelo Marques Moreira Filho
Chief Executive Officer

